Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma.

ABSTRACT:

Introduction

The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.

Methods

Patients with stages IVB and limited IVC BRAFV600E-negative ATC received immediate combination therapy consisting of the multikinase inhibitor (mKI) lenvatinib and the immune checkpoint inhibitor (ICI) pembrolizumab upon diagnosis. Patients with BRAFV600E-positive tumors were treated with a BRAF/MEK inhibitor regimen, consis

SUBMITTER: Wachter S 

PROVIDER: S-EPMC12414790 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature